851983-85-2 | Galaterone

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$33.00	$23.00
5mg	98%(HPLC)	in stock	$85.00	$60.00
25mg	98%(HPLC)	in stock	$254.00	$178.00
100mg	98%(HPLC)	in stock	$761.00	$533.00

Description

• Catalog Number: AH51129
• Chemical Name: Galaterone
• CAS Number: 851983-85-2
• Molecular Formula: C26H32N2O
• Molecular Weight: 388.5451
• MDL Number: MFCD16660907
• SMILES: O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2n2cnc3c2cccc3)C)C1)C

Computed Properties

• Complexity: 743
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 5.2

Literature

• Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

  BMC urology 20140101

• The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

  Current opinion in oncology 20120501

• Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.

  The Journal of biological chemistry 20120203

• Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.

  Nature 20120202

• Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

  Steroids 20111101

• CYP17 inhibitors for prostate cancer therapy.

  The Journal of steroid biochemistry and molecular biology 20110501

• Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

  British journal of cancer 20100928

• CYP17 inhibition as a hormonal strategy for prostate cancer.

  Nature clinical practice. Urology 20081101

• 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

  Molecular cancer therapeutics 20080901

• Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

  Molecular cancer therapeutics 20080801

• Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

  Molecular cancer therapeutics 20080101

• Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

  Journal of medicinal chemistry 20050421